Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tylenol Arthritis Pain Caplets on recall

This article was originally published in The Tan Sheet

Executive Summary

McNeil Consumer Healthcare expands a voluntary recall of its arthritis analgesic from five lots to all available lots following consumer reports of a moldy odor associated with the product. The Johnson & Johnson unit and FDA said Dec. 18 certain lots of the Tylenol Arthritis Pain product in 100-count bottles had traces of a chemical from treated wooden pallets, though all adverse events associated with the resulting odor have been temporary and non-serious. McNeil said it plans to move production to a new facility and reintroduce the product

You may also be interested in...



McNeil Expands Tylenol Recall As FDA Criticizes Firm's Response To AERs

McNeil Consumer Healthcare's reaction to signs of potentially contaminated packaging for OTC products including Tylenol raised FDA's ire and is now costing the firm an extensive product recall

Teva Concedes On US Gimoti ANDA, Voiding 180-Day Exclusivity

Teva will not engage in paragraph IV patent-infringement litigation with Evoke Pharma over the originator’s Gimoti (metoclopramide) nasal spray treatment for diabetic gastroparesis, following a court order.

Amgen Builds Up Future Launches As Oncology Biosimilars Slide

Amgen’s biosimilars sales are on the decline, largely due to erosion of its oncology portfolio. However, the debut of first US Humira rival Amjevita, along with planned versions of Stelara and Eylea, are expected to push the segment back into growth.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103670

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel